print page

Press Releases

 
2002 2003 2004 2005 all
 
 

 


Displaying releases: 1-15 | 16-30 | 31-45 | 46-60 | 61-75 | 76-90 | 91-105 | 106-120 | 121-135 | 136-150 | 151-165 | 166-180 | 181-195 | 196-210 | 211-225 | 226-240 | 241-255 | 256-270 | 271-285 | 286-300 | 301-315 | 316-321


  Feb-08-2016 Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction
  Feb-04-2016 Palatin Technologies to present at the BIO CEO & Investor Conference
  Dec-10-2015 Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction
  Nov-12-2015 Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2016 Results
  Nov-10-2015 Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2016 Results
  Sep-28-2015 Preclinical Data on PL-3994 for Heart Failure and Resistant Hypertension Presented at 2015 Heart Failure Society of America Annual Meeting
  Sep-21-2015 Palatin Technologies and Richter Terminate License Agreement for Bremelanotide for Female Sexual Dysfunction
  Sep-21-2015 Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2015 Results
  Sep-16-2015 Palatin Technologies, Inc. To Report Fourth Quarter Fiscal Year End 2015 Results
  Aug-18-2015 Palatin Technologies Supports FDAs Approval of the First-Ever Treatment for Female Sexual Dysfunction
  Jul-06-2015 Palatin Technologies Completes $30 Million Financing
  May-13-2015 Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2015 Results
  May-08-2015 Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2015 Results
  Mar-06-2015 Palatin Technologies to Present at the 27th Annual ROTH Conference
  Feb-20-2015 Palatin Launches reconnectstudy.com in Support of Bremelanotide Phase 3 Program for Female Sexual Dysfunction